title: Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
abstract: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections.
  
  
  
  This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events.
  
  
  
  23 eyes of 19 patients with CNV due to high myopia (9), macular telangiectasia (4), central serous chorioretinopathy (3), choroidal osteoma (2), choroiditis (2), Best's disease (2) and idiopathic (1) were treated. The mean follow-up period was 4±1.9 months. The median number of IVZ injections was 1 (range, 1-3) and the median treatment-free interval at the time of the final visit was 3 months (range, 1-8). The mean BCVA improved from 0.67 LogMAR to 0.58 LogMAR (p=0.0507). Nine of 23 (39%) eyes had BCVA gains of at least 0.1 LogMAR, 11 (48%) eyes had stable BCVA (within 0.1 LogMAR of baseline) and 3 (13%) eyes had a BCVA decline of at least 0.1 LogMAR at the final visit. The mean CMT improved significantly from baseline until the final visit (22 vs 174.5 μm; p=0.037). No ocular or systemic adverse events were noted.
  
  
  
  IVZ improves CMT in patients with CNV associated with causes other than AMD, but improvements in BCVA are modest.
authors.affiliation: School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana.|Srimati Kanuri Santhamma Centre for Vitreo-Retinal diseases, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Imoro Zeba
authors.initials: IZ
authors.lastname: Braimah
authors.affiliation: Department of Ophthalmology, Mayo Clinic, Jacksonville, Florida, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Stewart
authors.affiliation: Srimati Kanuri Santhamma Centre for Vitreo-Retinal diseases, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Chetan
authors.initials: C
authors.lastname: Videkar
authors.affiliation: Srimati Kanuri Santhamma Centre for Vitreo-Retinal diseases, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Chintan J
authors.identifier: 0000-0001-5475-2089
authors.initials: CJ
authors.lastname: Dedhia
authors.affiliation: Srimati Kanuri Santhamma Centre for Vitreo-Retinal diseases, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Jay
authors.initials: J
authors.lastname: Chhablani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000150:complications; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D008875:Middle Aged; D061848:Optical Imaging; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000150:complications; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
keywords: Retina